BioSig to Present at the Cowen & Co. 40th Annual Health Care
February 26 2020 - 8:33AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing a
proprietary biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that the Company will be
presenting at the Cowen & Co. 40th Annual Health Care
Conference. The Conference is being held on March 2-4, 2020 at the
Boston Marriott Copley Place in Boston, Massachusetts.
Kenneth L. Londoner, Chairman and CEO of BioSig Technologies,
Inc. will be presenting on overview of the Company as well as
recent developments and key highlights, including successfully
completing 100 patient cases with its PURE EP(tm) System, and its
recent participation at the 25th Annual International AF
Symposium.
The BioSig presentation will take place on Wednesday, March 4,
2020 at 8:00-8:30 AM in Orleans, 4th Floor. Mr.
Londoner will also be available for one-on-one meetings with
investor’s on Wednesday, March 4th. To schedule a one-on-one
meeting, please contact Andrew Ballou, Vice President, Investor
Relations at aballou@biosigtech.com.
About Cowen Inc. Cowen Inc. (“Cowen” or
the “Company”) is a diversified financial services firm offering
investment banking services, equity and credit research, sales and
trading, prime brokerage, global clearing, commission management
services and actively managed alternative investment products.
Cowen focuses on delivering value-added capabilities to our clients
in order to help them outperform. Founded in 1918, the Company is
headquartered in New York and has offices worldwide.
Learn more at Cowen.com
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve the
electrophysiology (EP) marketplace (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our products and
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024